$QS
QuantumScape Corp

2020 Q2 Form 10-Q Financial Statement

#000156459020037820 Filed on August 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $62.86K
YoY Change
% of Gross Profit
Research & Development $12.05M
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $14.23M
YoY Change
Operating Profit -$14.23M
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $281.0K
YoY Change
Pretax Income -$62.86K
YoY Change
Income Tax $0.00
% Of Pretax Income
Net Earnings -$13.95M
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share -$0.06
Diluted Earnings Per Share -$0.06
COMMON SHARES
Basic Shares Outstanding 239.8M
Diluted Shares Outstanding 239.8M

Balance Sheet

Concept 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.700M
YoY Change
Cash & Equivalents $29.18M
Short-Term Investments
Other Short-Term Assets $200.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.000M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $230.0M
YoY Change
Total Long-Term Assets $230.0M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $2.000M
Total Long-Term Assets $230.0M
Total Assets $232.0M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $300.0K
YoY Change
Accrued Expenses $100.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $100.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $500.0K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $8.100M
YoY Change
Total Long-Term Liabilities $8.100M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $500.0K
Total Long-Term Liabilities $8.100M
Total Liabilities $8.500M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $123.8M
YoY Change
Total Liabilities & Shareholders Equity $232.0M
YoY Change

Cashflow Statement

Concept 2020 Q2
OPERATING ACTIVITIES
Net Income -$13.95M
YoY Change
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$27.61K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$230.0M
YoY Change
Cash From Investing Activities -$230.0M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $25.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 231.8M
YoY Change
NET CHANGE
Cash From Operating Activities -27.61K
Cash From Investing Activities -230.0M
Cash From Financing Activities 231.8M
Net Change In Cash 1.740M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$27.61K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
230000000
CY2020Q2 us-gaap Franchisor Costs
FranchisorCosts
40548
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-62862
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5031247
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
13097867
CY2020Q2 kcac Value Of Shares Subject To Possible Redemption
ValueOfSharesSubjectToPossibleRedemption
218439270
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-62862
CY2020Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
25297
CY2020Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
227500
CY2020Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-207500
CY2020Q2 us-gaap Increase Decrease In Property And Other Taxes Payable
IncreaseDecreaseInPropertyAndOtherTaxesPayable
40548
CY2020Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27611
CY2020Q2 us-gaap Payments To Acquire Interest In Subsidiaries And Affiliates
PaymentsToAcquireInterestInSubsidiariesAndAffiliates
230000000
CY2020Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-230000000
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25000
CY2020Q2 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
75000
CY2020Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
230000000
CY2020Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6575000
CY2020Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4907692
CY2020Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
231767308
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1739697
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1739697
CY2020Q2 kcac Non Cash Offering Costs Included In Accrued Expenses
NonCashOfferingCostsIncludedInAccruedExpenses
117000
CY2020Q2 kcac Non Cash Offering Costs Included In Accounts Payable
NonCashOfferingCostsIncludedInAccountsPayable
23175
CY2020Q2 kcac Non Cash Deferred Underwriting Commissions In Connection With Initial Public Offering
NonCashDeferredUnderwritingCommissionsInConnectionWithInitialPublicOffering
8050000
CY2020Q2 us-gaap Stock Issued1
StockIssued1
218439270
CY2020Q2 kcac Non Cash Prepaid Expenses Included In Accrued Expenses
NonCashPrepaidExpensesIncludedInAccruedExpenses
207500
CY2020Q2 kcac Non Cash Prepaid Expenses Included In Accounts Payable
NonCashPrepaidExpensesIncludedInAccountsPayable
5000
CY2020Q2 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2020Q2 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the <font style="Background-color:#FFFFFF;">financial statements </font>in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2020Q2 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.00
CY2020Q2 kcac Maximum Net Tangible Assets For Business Combination
MaximumNetTangibleAssetsForBusinessCombination
5000001
CY2020Q2 kcac Percentage Of Public Shares To Be Redeemed
PercentageOfPublicSharesToBeRedeemed
1.00
CY2020Q2 kcac Interest To Pay Dissolution Expenses
InterestToPayDissolutionExpenses
100000
CY2020Q2 kcac Working Capital
WorkingCapital
1500000
CY2020Q2 kcac Proceeds From Sale Of Founders Shares
ProceedsFromSaleOfFoundersShares
25000
CY2020Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q2 kcac Concentrations Of Credit Risk Federal Depository Insurance Coverage Limit
ConcentrationsOfCreditRiskFederalDepositoryInsuranceCoverageLimit
250000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-62862
CY2020Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q2 kcac Description Of Public Warrant
DescriptionOfPublicWarrant
Each Unit consists of one share of Class A common stock and one-half of one redeemable warrant.
CY2020Q2 kcac Period To Issue Warrant After Completion Of Initial Business Combination
PeriodToIssueWarrantAfterCompletionOfInitialBusinessCombination
P30D
CY2020Q2 kcac Underwriting Discount Per Unit
UnderwritingDiscountPerUnit
0.20
CY2020Q2 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
4600000
CY2020Q2 kcac Deferred Underwriting Commission Per Unit
DeferredUnderwritingCommissionPerUnit
0.35
CY2020Q2 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
The Class B common stock will automatically convert into Class A common stock at the time of the initial Business Combination, or earlier at the option of the holders, on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and subject to further adjustment as described herein.
CY2020Q2 kcac Public Warrants Expiration Term
PublicWarrantsExpirationTerm
P5Y
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.50
CY2020Q2 kcac Minimum Share Price Required For Redemption Of Warrants
MinimumSharePriceRequiredForRedemptionOfWarrants
18.00
CY2020Q2 kcac Percentage Of Proceeds From Share Issuances
PercentageOfProceedsFromShareIssuances
0.60
CY2020Q2 kcac Exercise Price Adjustment Percentage
ExercisePriceAdjustmentPercentage
1.15
CY2020Q2 kcac Redemption Trigger Price Adjustment Percentage
RedemptionTriggerPriceAdjustmentPercentage
1.80

Files In Submission

Name View Source Status
0001564590-20-037820-index-headers.html Edgar Link pending
0001564590-20-037820-index.html Edgar Link pending
0001564590-20-037820.txt Edgar Link pending
0001564590-20-037820-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kcac-10q_20200630.htm Edgar Link pending
kcac-20200630.xml Edgar Link completed
kcac-20200630.xsd Edgar Link pending
kcac-20200630_cal.xml Edgar Link unprocessable
kcac-20200630_def.xml Edgar Link unprocessable
kcac-20200630_lab.xml Edgar Link unprocessable
kcac-20200630_pre.xml Edgar Link unprocessable
kcac-ex311_7.htm Edgar Link pending
kcac-ex312_8.htm Edgar Link pending
kcac-ex321_6.htm Edgar Link pending
kcac-ex322_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending